Guilford Pharmaceuticals (MM) News - GLFD

Guilford Pharmaceuticals Announces Phase III AQUAVAN(R) Trial Meets Primary Endpoint

Guilford Pharmaceuticals Announces Phase III AQUAVAN(R) Trial Meets Primary Endpoint BALTIMORE, March 24 /PRNewswire-FirstCall/ -- Guilford...

Guilford Pharmaceuticals: AGGRASTAT(R) Injection Clinical Data Presented at American College of Cardiology Annual Meeting

Guilford Pharmaceuticals: AGGRASTAT(R) Injection Clinical Data Presented at American College of Cardiology Annual Meeting BALTIMORE, March 8...

Guilford Pharmaceuticals Reports 2004 Year-End Financial Results

Guilford Pharmaceuticals Reports 2004 Year-End Financial Results BALTIMORE, March 1 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals...

Guilford Pharmaceuticals to Announce 2004 Year-End Financial Results on Tuesday, March 1, 2005

Guilford Pharmaceuticals to Announce 2004 Year-End Financial Results on Tuesday, March 1, 2005 BALTIMORE, Feb. 10 /PRNewswire-FirstCall/...

Guilford Pharmaceuticals to Announce 2004 Year-End Financial Results on Tuesday, March 1, 2005

Guilford Pharmaceuticals to Announce 2004 Year-End Financial Results on Tuesday, March 1, 2005 BALTIMORE, Feb. 10 /PRNewswire-FirstCall/...

Guilford Pharmaceuticals Completes Sale and Leaseback and Receives $19.4 Million in Net Proceeds

Guilford Pharmaceuticals Completes Sale and Leaseback and Receives $19.4 Million in Net Proceeds BALTIMORE, Dec. 17 /PRNewswire-FirstCall/...

Guilford Pharmaceuticals to Acquire ProQuest Pharmaceuticals; Guilford to Obtain Exclusive Worldwide Ownership of AQUAVAN(R) Pro

Guilford Pharmaceuticals to Acquire ProQuest Pharmaceuticals; Guilford to Obtain Exclusive Worldwide Ownership of AQUAVAN(R) Prodrug Technology...

Guilford Pharmaceuticals Presents New GLIADEL(R) Wafer Data at the Society for Neuro-Oncology Annual Meeting

Guilford Pharmaceuticals Presents New GLIADEL(R) Wafer Data at the Society for Neuro-Oncology Annual Meeting BALTIMORE, Nov. 22...

Guilford Pharmaceuticals Announces Equity Compensation Arrangement With Dean J. Mitchell Pursuant to NASDAQ Rules

Guilford Pharmaceuticals Announces Equity Compensation Arrangement With Dean J. Mitchell Pursuant to NASDAQ Rules BALTIMORE, Nov. 17...

Dean J. Mitchell Appointed President and Chief Executive Officer of Guilford Pharmaceuticals

Dean J. Mitchell Appointed President and Chief Executive Officer of Guilford Pharmaceuticals BALTIMORE, Nov. 17 /PRNewswire-FirstCall/...

AGGRASTAT(R) Strategy Trial Data Presented At American Heart Association Annual Meeting

AGGRASTAT(R) Strategy Trial Data Presented At American Heart Association Annual Meeting Guilford's Phase III Development Plan Progresses;...

Guilford Pharmaceuticals Reports 2004 Third Quarter Results

Guilford Pharmaceuticals Reports 2004 Third Quarter Results BALTIMORE, Nov. 8 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals...

Guilford Pharmaceuticals to Announce Third Quarter 2004 Financial Results on Monday, November 8, 2004

Guilford Pharmaceuticals to Announce Third Quarter 2004 Financial Results on Monday, November 8, 2004 BALTIMORE, Nov. 5 /PRNewswire-FirstCall/...

Guilford Pharmaceuticals Announces Orphan Drug Designation for GLIADEL(R) Wafer; Market Exclusivity for GLIADEL(R) Extends Until

Guilford Pharmaceuticals Announces Orphan Drug Designation for GLIADEL(R) Wafer; Market Exclusivity for GLIADEL(R) Extends Until 2010 BALTIMORE...

Guilford to Present at UBS Global Life Sciences Conference

Guilford to Present at UBS Global Life Sciences Conference BALTIMORE, Sept. 22 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Guilford Pharmaceuticals (MM) (GLFD)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

GLFD News

Guilford Pharmaceuticals Announces Phase III AQUAVAN(R) Trial Meets Primary Endpoint

Guilford Pharmaceuticals: AGGRASTAT(R) Injection Clinical Data Presented at American College of Cardiology Annual Meeting

Guilford Pharmaceuticals Reports 2004 Year-End Financial Results

Guilford Pharmaceuticals to Announce 2004 Year-End Financial Results on Tuesday, March 1, 2005

Guilford Pharmaceuticals to Announce 2004 Year-End Financial Results on Tuesday, March 1, 2005

Guilford Pharmaceuticals Completes Sale and Leaseback and Receives $19.4 Million in Net Proceeds

Guilford Pharmaceuticals to Acquire ProQuest Pharmaceuticals; Guilford to Obtain Exclusive Worldwide Ownership of AQUAVAN(R) Pro

Guilford Pharmaceuticals Presents New GLIADEL(R) Wafer Data at the Society for Neuro-Oncology Annual Meeting

Guilford Pharmaceuticals Announces Equity Compensation Arrangement With Dean J. Mitchell Pursuant to NASDAQ Rules

Dean J. Mitchell Appointed President and Chief Executive Officer of Guilford Pharmaceuticals

AGGRASTAT(R) Strategy Trial Data Presented At American Heart Association Annual Meeting

Guilford Pharmaceuticals Reports 2004 Third Quarter Results

Guilford Pharmaceuticals to Announce Third Quarter 2004 Financial Results on Monday, November 8, 2004

Guilford Pharmaceuticals Announces Orphan Drug Designation for GLIADEL(R) Wafer; Market Exclusivity for GLIADEL(R) Extends Until

Guilford to Present at UBS Global Life Sciences Conference

GLFD Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Guilford Pharmaceuticals (MM) (GLFD) News

Guilford Pharmaceuticals (MM) (GLFD)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

GLFD News

Guilford Pharmaceuticals Announces Phase III AQUAVAN(R) Trial Meets Primary Endpoint

Guilford Pharmaceuticals: AGGRASTAT(R) Injection Clinical Data Presented at American College of Cardiology Annual Meeting

Guilford Pharmaceuticals Reports 2004 Year-End Financial Results

Guilford Pharmaceuticals to Announce 2004 Year-End Financial Results on Tuesday, March 1, 2005

Guilford Pharmaceuticals to Announce 2004 Year-End Financial Results on Tuesday, March 1, 2005

Guilford Pharmaceuticals Completes Sale and Leaseback and Receives $19.4 Million in Net Proceeds

Guilford Pharmaceuticals to Acquire ProQuest Pharmaceuticals; Guilford to Obtain Exclusive Worldwide Ownership of AQUAVAN(R) Pro

Guilford Pharmaceuticals Presents New GLIADEL(R) Wafer Data at the Society for Neuro-Oncology Annual Meeting

Guilford Pharmaceuticals Announces Equity Compensation Arrangement With Dean J. Mitchell Pursuant to NASDAQ Rules

Dean J. Mitchell Appointed President and Chief Executive Officer of Guilford Pharmaceuticals

AGGRASTAT(R) Strategy Trial Data Presented At American Heart Association Annual Meeting

Guilford Pharmaceuticals Reports 2004 Third Quarter Results

Guilford Pharmaceuticals to Announce Third Quarter 2004 Financial Results on Monday, November 8, 2004

Guilford Pharmaceuticals Announces Orphan Drug Designation for GLIADEL(R) Wafer; Market Exclusivity for GLIADEL(R) Extends Until

Guilford to Present at UBS Global Life Sciences Conference

GLFD Discussion

Your Recent History